Peripartum myocardiopathy after cesarean section: case report
Fernando Brito Cançado. Thais Orrico de Brito Cançado, Fabio Brito Cançado, Melina Brito Cançado, Felipe Grieco Paglioli
Abstract
Peripartum myocardiopathy is a form of systolic heart failure involving reduced ventricular ejection fraction (EF<45%), affecting mainly pregnant women in the period close to the newborn birth. The incidence varies globally and is more prevalent in pregnant women of African descent, aged over 30 years, with a history of hypertension and pre-eclampsia and multiple pregnancies. The clinical condition may be mild, but cardiac mechanical support may be necessary in severe cases. The aim of this report is to present a case of a pregnant woman who was admitted to the maternity ward in labor together with cardiac decompensation during cesarean section due to peripartum myocardiopathy. We have reviewed the literature and suggest a better understanding of the disease is urgently needed, especially among anesthesiologists. Thus, early diagnosis and appropriate therapy can improve favorable outcomes.
Keywords
References
1. Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, et al. Pathophysiology, diagnosis, and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019;21(7):827-43. http://doi.org/10.1002/ejhf.1493 PMid:31243866.
2. Isogai T, Kamiya CA. Worldwide Incidence of Peripartum Cardiomyopathy and Overall Maternal Mortality. Int Heart J. 2019;60(3):503-11. http://doi.org/10.1536/ihj.18-729 PMid:31019181.
3. Sliwa K, Petrie MC, van der Meer P, Mebazaa A, Hilfiker-Kleiner D, Jackson AM, et al. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J. 2020;41(39):3787-97. http://doi.org/10.1093/eurheartj/ehaa455 PMid:32840318.
4. Viljoen C, Hoevelmann J, Sliwa K. Peripartum cardiomyopathy: risk factors and predictors of outcome. Curr Opin Cardiol. 2023;38(3):223-32. http://doi.org/10.1097/HCO.0000000000001037 PMid:36928005.
5. Kholt D, Khera SWS, Aronow WS, Palaniswamy C, Mujib M, Ahn C, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc. 2014;3(3):e001056. http://doi.org/10.1161/JAHA.114.001056 PMid:24901108.
6. Bala R, Mehta S, Roy VC, Kaur G, de Marvao A. Peripartum cardiomyopathy: a review. Rev Port Cardiol. 2023;42(11):917-24. http://doi.org/10.1016/j.repc.2023.01.029 PMid:37414337.
7. Kryczka KE, Demkow M, Dzielińska Z. Biomarkers in peripartum cardiomyopathy-what we know and what is still to be found. Biomolecules. 2024;14(1):103. http://doi.org/10.3390/biom14010103 PMid:38254703.
8. Sliwa K, Förster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006;27(4):441-6. http://doi.org/10.1093/eurheartj/ehi481 PMid:16143707.
9. Yaniv-Salem S, Dym L, Nesher L, Zahger D, Shalev A, Shmueli H. post-COVID-19 Peripartum Cardiomyopathy: Experience from a Large Tertiary Referral Center. Isr Med Assoc J. 2023;25(8):533-7. PMid:37574890.
10. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, Bonis M, Iung B, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-241. http://doi.org/10.1093/eurheartj/ehy340 PMid:30165544.
11. Cunningham FG, Byrne JJ, Nelson DB. Peripartum cardiomyopathy. Obstet Gynecol. 2019;133(1):167-79. http://doi.org/10.1097/AOG.0000000000003011 PMid:30575651.
12. Sliwa K, van der Meer P, Viljoen C, Jackson AM, Petrie MC, Mebazaa A, et al. Socio-economic factors determine maternal and neonatal outcomes in women with peripartum cardiomyopathy: A study of the ESC EORP PPCM registry. Int J Cardiol. 2024;398:131596. http://doi.org/10.1016/j.ijcard.2023.131596 PMid:37979788.
13. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema J-P, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121(13):1465-73. http://doi.org/10.1161/CIRCULATIONAHA.109.901496 PMid:20308616.
14. Imran TF, Ataklte F, Khalid M, Lopez D, Mohebali D, Bello NA, et al. Clinical predictors of right ventricular dysfunction and association with adverse outcomes in peripartum cardiomyopathy. ESC Heart Fail. 2024;11(1):422-32. http://doi.org/10.1002/ehf2.14583 PMid:38030384.
15. Sonigra KJ, Nyambura E, Mwangi O, Sarna K, Omanwa K. Successful management of peripartum cardiomyopathy in a Kenyan setting: a case series. Pan Afr Med J. 2023;44:150. http://doi.org/10.11604/pamj.2023.44.150.38455 PMid:37396700.
16. Zhang Z, Zheng W, Chen M, Huang M, Li W, Huang Z, et al. A new risk score for the assessment of outcomes for Chinese patients with peripartum cardiomyopathy. Heart Lung. 2023;60:81-86. https://doi.org/10.1016/j.hrtlng.2023.02.021 PMid:36933287.
17. Jackson AM, Macartney M, Brooksbank K, Brown C, Dawson D, Francis M, et al. A 20-year population study of peripartum cardiomyopathy. Eur Heart J. 2023;44(48):5128-41. http://doi.org/10.1093/eurheartj/ehad626 PMid:37804234.
18. Avila WS, Alexandre ERG, de Castro ML, Lucena AJG, Marques-Santos C, Freire CMV, et al. Posicionamento da Sociedade Brasileira de Cardiologia para Gravidez e Planejamento Familiar na Mulher Portadora de Cardiopatia – 2020. Arq Bras Cardiol. 2020;114(5):849-942. http://doi.org/10.36660/abc.20200406 PMid:32491078.
19. Bordignon S. Cardiomiopatia periparto: contraindicação para subsequentes gravidezes. Rev Soc Cardiol Rio Grande do Sul. 2007;11.
Submitted date:
08/07/2024
Accepted date:
06/19/2024
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email